The current treatment options for Raynaud phenomenon are often ineffective and can have undesirable adverse effects. Topical, or transdermal, treatments that increase digital blood flow without systemic adverse effects are, therefore, an attractive option. A novel topical nitroglycerin formulation has shown promise in treating Raynaud attacks.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chung, L. et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon. Arthritis Rheum. 60, 870–877 (2009).
Kleckner, M. S., Allen, E. V. & Wakim, K. G. The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud's disease and Raynaud's phenomenon: studies on blood flow and clinical manifestations. Circulation 3, 681–689 (1951).
Francks, A. G. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet 1, 76–77 (1982).
Anderson, M. E. et al. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxf.) 41, 324–328 (2002).
Teh, L. S. et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br. J. Rheumatol. 34, 636–641 (1995).
Merkel, P. A. et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum. 46, 2410–2420 (2002).
Thompson, A. E. & Pope, J. E. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxf.) 44, 145–150 (2005).
Thompson, A. E., Shea, B., Welch, V., Fenlon, D. & Pope, J. E. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 44, 1841–1847 (2001).
Belch, J. et al. MQX-503, a novel topical nitroglycerin formulation, improves severity of symptoms associated with Raynaud's phenomenon. Arthritis Rheum. 58 (Suppl.), S622 (2008).
Lewis, T. Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease. Heart 15, 7–101 (1929).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declared that she has received grant/research support from Mediquest Therapeutics.
Rights and permissions
About this article
Cite this article
Herrick, A. A local approach to Raynaud phenomenon. Nat Rev Rheumatol 5, 246–247 (2009). https://doi.org/10.1038/nrrheum.2009.64
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2009.64
This article is cited by
-
Assessing microvascular changes in systemic sclerosis diagnosis and management
Nature Reviews Rheumatology (2010)
